Side-by-side · Research reference

CagrilintidevsCJC-1295 (no DAC)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED35/64 cited

BPhase 1HUMAN-REVIEWED7/51 cited

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer dose

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

01Mechanism of Action

Parameter

Cagrilintide

CJC-1295 (no DAC)

Primary target

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

Pituitary GHRH receptorTeichman 2006

Pathway

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosis

Downstream effect

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Feedback intact?

Yes — acts via physiological amylin pathways

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Origin

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistance

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Cagrilintide

CJC-1295 (no DAC)

Standard dose (combination)

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

—

Monotherapy dosing

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

—

Frequency

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

1–2× daily (pre-sleep ± morning)

Evidence basis

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Duration

26–52 weeks in trialsYamauchi 2026

8–12 weeks on / 4 off (anecdotal)

Route

Subcutaneous injectionBailey 2026

—

Standard dose

—

100 mcg per injection

Often paired with ipamorelin in same syringe.

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

03Metabolic / Fat Loss Evidence

Parameter

Cagrilintide

CJC-1295 (no DAC)

Weight loss vs semaglutide

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

—

Absolute weight change

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

—

Mechanism

Central satiety inductionBailey 2026

—

BMI reduction

Significant BMI reduction vs comparatorAhmed 2026

—

Glycemic benefit

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

—

Lipid effects

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

—

Body composition

Predominant fat loss with weight reduction

—

Mitochondrial function

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

—

Combination rationale

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

—

Key publications

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

—

04Side Effects & Safety

Parameter

Cagrilintide

CJC-1295 (no DAC)

Gastrointestinal

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

—

Injection site reactions

Local reactions possible with subcutaneous administration

—

Safety profile

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

—

Tolerability

Tolerability considerations similar to GLP-1RAs

—

Muscle preservation

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

—

Injection site reaction

—

Erythema, mild pruritus

Flushing / headache

—

Common transient effect

Cortisol elevation

—

Minimal at standard doses

Prolactin elevation

—

Minimal

Glucose intolerance

—

Possible at high cumulative doses

IGF-1 elevation

—

Dose-dependent; monitor with chronic use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

Cagrilintide

CJC-1295 (no DAC)

1. Dosing frequency

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

2. Combination form

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

Subcutaneous, abdomen or thigh. Rotate sites.

3. Injection site

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

4. Storage

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Dietary considerations

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition